NanoViricides to Present at the PODD 2025 Conference in Boston on October 27

Impact · against what's priced in

NanoViricides provides material updates on its clinical pipeline, specifically the transition of NV-387 to Phase II trials for MPox and the planning of a broad-spectrum respiratory trial. The shift from animal models to human Phase II trials represents a significant de-risking event for the lead candidate's commercial path.

NNVC+0.60

No priced-in read yet

In context

The transition of NV-387 into Phase II clinical trials for MPox in the DRC and the planning of a separate Phase II trial for respiratory infections move the lead candidate beyond animal model success into human efficacy testing.

Read from the article alone

• biotech
• NNVC
• antivirals
• clinical trials
• drug pipeline
• healthcare conference
• measles
• mpox
• phase ii
• respiratory infection
• rsv